Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study

Figure 1 Histological appearance of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis at 100 × magnification (hematoxylin and eosin stain). A: A non-alcoholic fatty liver diseases activity score (NAS) 3/8; B: A NAS 6/8 which constitutes a moderate-severe steatohepatitis. Blue triangles denote macrovesicular steatosis. Black stars denote ballooned hepatocytes. Black bars in lower right corner denote scale bar of 50 μm.

Figure 2 Patient demographic flow chart. The chart demonstrates the total number of metabolic dysfunction-associated steatohepatitis patients in both United States and University of Texas Medical Branch cohorts, total number of Hispanic/Latino and non-Hispanic/Latino patients in each cohort, the effects of Propensity Score Matching on cohort size, and the total number of male and female patients in each sub-cohort. MASH: Metabolic dysfunction-associated steatohepatitis; UTMB: University of Texas Medical Branch; HCO: Healthcare organizations.

Figure 3 Kaplan-Meier survival analysis curves for United States and University of Texas Medical Branch cohorts. Hispanic/Latino patients are represented in red, while non-Hispanic/Latino patients are represented in blue. The four primary outcomes (all-cause mortality, hepatocellular carcinoma, type 2 diabetes mellitus, and fibrosis/cirrhosis of the liver) are represented for both cohorts. MASH: Metabolic dysfunction-associated steatohepatitis; UTMB: University of Texas Medical Branch; HCC: Hepatocellular carcinoma; T2DM: Type 2 diabetes mellitus.